Britain’s competition watchdog announced on Thursday, June 27, it would launch an in-depth investigation into the planned US$1.2 billion merger between gene sequencing company Illumina and smaller rival Pacific Biosciences of California.
The Competition and Markets Authority (CMA) stated it would refer the merger to a second phase investigation after the companies refused to address concerns the watchdog had raised last week.
The CMA’s initial—or first phase—investigation had raised concerns about the deal’s impact on the supply of specialist DNA sequencing systems in the UK.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
